Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939428 · ClinicalTrials.gov registry record · Phase 3
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,441
- Enrollment target
NCT04939428 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 2,441 participants.
The verdict
NCT04939428, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,441 participants
- Enrollment target
Study Summary
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.
Interventions
- DRUG Placebo
- DRUG Molnupiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,441 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04939428
The ClinicalTrials.gov registry entry for NCT04939428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,441 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04939428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04939428 about?
NCT04939428 is a clinical study titled "Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)". The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; ha...
What is the current status of trial NCT04939428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,441 participants. The study started on 2021-08-11. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT04939428?
The interventions under investigation include: Placebo (DRUG), Molnupiravir (DRUG).
Who is sponsoring clinical trial NCT04939428?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.